無菌注射薬の製造委託アウトソーシング（CMO）市場レポート：2024-2034

Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Report 2024-2034

レポート詳細無菌注射薬の製造委託アウトソーシング（CMO）市場レポート 2024-2034年：本レポートは、業界とその基礎となる原動力をよりよく理解したいと望むなら、新たな収益ポケットを目指す大手... もっと見る

出版社	出版年月	電子版価格	ページ数	図表数	言語
Visiongain ヴィジョンゲイン社	2023年10月25日	GBP5,150 部署ライセンスライセンス・価格情報・注文方法はこちら	428	424	英語

※上記価格は部署ライセンス（Departmental licence）価格です。
その他の価格についてはデータリソースまでお問合せください。
日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。

目次
図表リスト

サマリー

レポート詳細

無菌注射薬の製造委託アウトソーシング（CMO）市場レポート 2024-2034年：本レポートは、業界とその基礎となる原動力をよりよく理解したいと望むなら、新たな収益ポケットを目指す大手企業にとって貴重なものとなるでしょう。また、異業種への進出や新規地域での既存事業の拡大を目指す企業にも有用です。

医薬品研究開発への投資の増加と生物学的製剤の需要増加が市場成長を牽引
製薬業界では研究開発への投資が盛んに行われており、先進的な企業では売上高の平均15%を研究開発に充てている。多くの製薬企業が新薬や治療法の開発に役立てるため、研究開発費を増やしている。2022年には、ロシュ、ファイザー、メルク、ブリストル・マイヤーズスクイブなどの大手製薬会社は、年間売上高の約5分の1を研究開発費に充てることになる。医薬品研究開発費の急増の結果、無菌注射薬の製造委託アウトソーシング（CMO）のニーズが拡大し、CMOにアウトソーシングサービスを提供する機会が増えると予測される。

その結果、多くの人々が製造のアウトソーシングなど、コスト削減の選択肢を検討するようになった。より多くの特許が失効する予定であり、生物製剤や新規化学物質の発掘に向けた取り組みが増え、研究開発費が高騰しているため、医薬品メーカーやスポンサーは、ジェネリック医薬品によってもたらされた経済的損失を埋め合わせなければならないというプレッシャーにさらされている。このため、医薬品研究はさらに高価で複雑なものとなっている。政府機関でさえ、必要なツールや専門知識を利用するため、またコストや外注期間を削減するために、CROに臨床生産を委託している。

高いオペレーションコストが業界の成長を阻む
高いオペレーションコストが世界的な収益の増加を妨げている。無菌医薬品を製造する際には、高度な設備を使用する必要がある。例えば、あるバイオテクノロジー企業が、腫瘍学の第I-II相臨床試験を実施するために、注射薬のバイアルを3,000本作成する必要があるかもしれない（無菌充填と仕上げ）。医薬品を製造するために予想される費用は以下の通りである：プロジェクト計画と管理：35,000ドル、サプライヤー管理：4,000ドル、医薬品分析開発：40,000ドル。バイオテクノロジー企業は、製造業務を別の医薬品製造受託機関（CDMO）に委託すると思われる。さらに、無菌注射医薬品の製造、包装、保管、流通に細心の注意を払うことを義務付けているFDAの要件により、運用コストの負担は大きく、CMO市場の成長を妨げる可能性がある。

市場調査レポートを購入する前にすべき質問とは？
- 無菌注射薬の製造委託アウトソーシング（CMO）市場はどのように進化しているのか？
- 何が無菌注射薬の製造委託アウトソーシング（CMO）市場を促進し、抑制しているのか？
- ポイントオブケア診断の各サブ市場セグメントは予測期間中にどのように成長し、2034年にはどれくらいの売上を占めるようになるのか？
- 2024年から2034年にかけて、無菌注射薬の製造委託アウトソーシング（CMO）各サブマーケットの市場シェアはどのように推移するのか？
- 2024年から2034年にかけて市場全体の主な牽引役は何か？
- 主要な無菌注射剤製造委託（CMO）市場はマクロ経済の動きに大枠で追随するのか、それとも個々の国市場が他を凌駕するのか？
- 2034年までに各国市場のシェアはどのように変化し、どの地域が2034年の市場をリードするのか？
- 主要プレーヤーは誰で、予測期間中の見通しは？
- これらの大手企業による無菌注射薬の製造委託アウトソーシング（CMO）プロジェクトとは？
- 2024年から2034年の間に、業界はどのように発展するのか？現在および今後10年間に実施される無菌注射薬の製造委託アウトソーシング（CMO）プロジェクトにはどのような意味があるのか？
- 無菌注射薬の製造委託アウトソーシング（CMO）市場をさらに拡大するために、製品の商業化の必要性は高まっていますか？
- 無菌注射薬の製造委託アウトソーシング（CMO）市場はどこに向かっており、どのようにすれば市場の最前線に立てるのか？
- 新製品やサービスラインに対する最適な投資オプションは何か？
- 企業を新たな成長軌道に乗せ、C-suiteに移行させるための重要な展望とは？

無菌注射薬の製造委託アウトソーシング（CMO）市場が現在、そして今後10年間でどのような影響を受けるかを知る必要があります：
- 428ページにわたる本レポートでは、170の表、254の図表、グラフを掲載しています。
- 本レポートでは、業界における主要な有利分野をハイライトしているため、今すぐターゲットを絞ることができます。
- 世界、地域、国別の売上高と成長率を詳細に分析しています。
- 競合他社が成功した主なトレンド、変化、収益予測をハイライトしています。

本レポートは、無菌注射薬の製造委託アウトソーシング（CMO）市場が今後10年間でどのように発展するか、またCOVID-19の景気後退と好転の変動に合わせてどのように発展するかをお伝えします。この市場は、過去10年間のどの時点よりも今が重要です。

2034年までの予測やその他の分析から、商業的な展望が明らかになる
- 2034年までの収益予測に加え、直近の実績、成長率、市場シェアを提供します。
- ビジネスの展望と展開に関する独自の分析をご覧いただけます。
- 定性分析（市場ダイナミクス、促進要因、機会、阻害要因、課題など）、コスト構造、無菌注射薬の製造委託アウトソーシング（CMO）価格上昇の影響、最近の動向などをご覧いただけます。

本レポートには、COVID-19が業界と貴社にどのような影響を与えるかについてのデータ分析と貴重な洞察が含まれている。本レポートでは、COVID-19の4つの回収パターンとその影響、すなわち「V」、「L」、「W」、「U」について論じている。

レポート対象セグメント

分子タイプ
- 小分子
- 大分子

タイプ
- モノクローナル抗体
- サイトカイン
- インスリン
- ペプチドホルモン
- ワクチン
- 免疫グロブリン
- 血液因子
- ペプチド抗生物質
- その他のタイプ

用途
- 癌
- 糖尿病
- 心血管疾患
- 中枢神経系
- 感染症
- その他

容器タイプ
- ボトル
- アンプル
- バイアル
- プレフィルドシリンジ
- バッグ

投与経路
- 皮下
- 静脈内
- 筋肉内
- その他の投与経路

サービス
- バイオ分析試験
- 試験法開発およびバリデーション
- 安定性試験
- その他

世界市場全体と各分野の収益予測に加え、5つの地域と18の主要国市場の収益予測も掲載しています：

北米
- アメリカ
- カナダ

欧州
- ドイツ
- 英国
- フランス
- イタリア
- スペイン
- スイス
- オランダ
- その他の欧州

アジア太平洋
- 中国
- 日本
- インド
- オーストラリア
- 韓国
- 東南アジア
- その他のアジア太平洋地域

ラテンアメリカ
- ブラジル
- メキシコ
- アルゼンチン
- その他のラテンアメリカ

MEA
- GCC
- 南アフリカ
- エジプト
- その他のMEA

また、無菌注射薬の製造委託アウトソーシング（CMO）市場の2024年から2034年までの主要企業のプロファイルと、これらの企業の事業のこのセグメントに焦点を当てています。

主要企業と市場成長の可能性
・ Adare Pharma Solutions
・ Aenova Group
・ Almac Group
・ Avara Pharmaceutical サービスs, Inc.
・ Boehringer Ingelheim International GmbH
・ Catalent, Inc.
・ CordenPharma International
・ Evonik Industries AG
・ F. Hoffmann-La Roche Ltd.
・ FAMAR Health Care サービスs
・ Fresenius Kabi AG
・ Grifols, S.A.
・ Hikma Pharmaceuticals PLC
・ Jubilant Pharmova Limited
・ Lilly
・ Lonza
・ Nexus Pharmaceuticals, LLC
・ Patheon Pharma サービスs (Thermo Fisher Scientific Inc.)
・ Pfizer Inc.
・ Piramal Pharma Solutions
・ Recipharm AB
・ Siegfried Holding AG
・ Vetter Pharma
・ Wuxi AppTec

2024年から2034年までの無菌注射薬の製造委託アウトソーシング（CMO）市場における世界全体の売上高は、金額ベースで2024年に242億米ドルを突破すると当研究所は算出した。2034年まで力強い収益成長を予測している。当社の調査では、最も大きな可能性を秘めた企業を特定。各組織の能力、進捗状況、商業的展望を把握することで、常に一歩先を行くことができます。

無菌注射薬の製造委託アウトソーシング（CMO）市場、2024〜2034年レポートはどのようにお役に立ちますか？
要約すると、420ページを超えるこのレポートは、以下の知識を提供する：

- 無菌注射薬の製造委託アウトソーシング（CMO）市場の2034年までの収益予測、タイプ、分子タイプ、用途、容器タイプ、投与経路、サービスごとの予測を世界および地域レベルで掲載 - 業界の将来性を発見し、投資と収益に最も有利な場所を見つけることができます。

- 5つの地域と21の主要国市場の2034年までの収益予測 - 北米、ヨーロッパ、アジア太平洋、ラテンアメリカ、MEAの無菌注射薬製造委託アウトソーシング（CMO）市場の2024年から2034年までの予測をご覧ください。また、米国、カナダ、メキシコ、ブラジル、ドイツ、フランス、英国、イタリア、スペイン、スイス、オランダ、中国、インド、日本、オーストラリア、韓国、東南アジア、アルゼンチン、GCC、南アフリカ、エジプトなどの著名経済圏の市場も予測しています。

- 既存企業や市場参入を目指す企業の展望 - 無菌注射薬の製造委託アウトソーシング（CMO）市場に関わる主要企業25社の企業プロファイルを含む、2024年から2034年までの市場。

独自の予測による定量的・定性的分析をご覧ください。私たちのレポートだけに含まれる情報を入手し、貴重なビジネスインテリジェンスで情報を得ることができます。

他にはない情報
私たちの新しいレポートがあれば、知識に遅れをとったり、チャンスを逃したりする可能性が低くなります。弊社のレポートが貴社の調査、分析、意思決定にどのように役立つかをご覧ください。Visiongainの調査は、2024年から2034年までの無菌注射薬の製造委託アウトソーシング（CMO）市場の商業分析を必要とするすべての人、市場をリードする企業のためのものです。データ、トレンド、予測をご覧いただけます。

ページTOPに戻る

1 レポート概要
1.1 研究の目的
1.2 無菌注射薬のCMO市場の紹介
1.3 本レポートの内容
1.4 本レポートを読むべき理由
1.5 本分析レポートが回答する主な質問
1.6 本レポートの対象者
1.7 方法論
1.7.1 市場の定義
1.7.2 市場評価・予測手法
1.7.3 データの検証
1.7.3.1 一次調査
1.7.3.2 セカンダリーリサーチ
1.8 よくある質問（FAQ）
1.9 Visiongainの関連レポート
1.10 Visiongainについて

2 エグゼクティブ・サマリー

3 市場概要
3.1 主要な調査結果
3.2 市場ダイナミクス
3.2.1 市場促進要因
3.2.1.1 癌治療開発への注目の高まり
3.2.1.2 慢性疾患の有病率の上昇
3.2.1.3 FDAによる無菌注射薬の急速な承認が市場成長を促進する
3.2.1.4 メーカーが新たな製造施設に投資するにつれて、無菌注射剤の需要は増加すると予想される
3.2.1.5 生物学的製剤の需要増加が需要を牽引すると予想される
3.2.1.6 医薬品研究開発への投資の増加
3.2.2 市場抑制要因
3.2.2.1 小規模メーカーとの競争激化
3.2.2.2 高い運用コスト
3.2.2.3 発展途上国における不十分な医療インフラが市場成長を阻む
3.2.3 市場機会
3.2.3.1 プレフィルドシリンジは有利な成長展望を提供する
3.2.3.2 投資の拡大
3.2.3.3 アジア太平洋地域における臨床試験の機会拡大
3.3 COVID-19の影響分析
3.4 ポーターのファイブフォース分析
3.4.1 競争上のライバル
3.4.2 新規参入の脅威
3.4.3 代替品の脅威
3.4.4 買い手の交渉力
3.4.5 供給者の交渉力
3.5 SWOT分析
3.6 PEST分析
3.6.1 無菌注射剤CMO市場に影響を与える政治的要因
3.6.2 無菌注射剤CMO市場に影響を与える経済的要因
3.6.3 無菌注射剤CMO市場に影響を与える社会的要因
3.6.4 CMO注射剤市場に影響を与える技術的要因

4 無菌注射薬のCMO市場分析：分子タイプ別
4.1 主要な調査結果
4.2 分子タイプ別セグメント市場魅力度指数
4.3 分子タイプ別無菌注射薬の製造委託アウトソーシング（CMO）市場規模推定と予測
4.4 小分子
4.4.1 2024〜2034年の地域別市場規模（US$ Billion）
4.4.2 地域別市場シェア、2024年・2034年(%)
4.5 大分子
4.5.1 2024〜2034年の地域別市場規模（US$ Billion）
4.5.2 地域別市場シェア、2024年・2034年(%)

5 無菌注射薬の製造委託アウトソーシング（CMO）市場：タイプ別、2024-2034年
5.1 主要調査結果
5.2 タイプ別セグメント市場魅力度指数
5.3 無菌注射薬の製造委託アウトソーシング（CMO）市場：タイプ別
5.4 モノクローナル抗体（mAbs）
5.4.1 2024〜2034年の地域別市場規模（US$ Billion）
5.4.2 地域別市場シェア、2024年・2034年(%)
5.5 サイトカイン
5.5.1 2024〜2034年の地域別市場規模（US$ Billion）
5.5.2 地域別市場シェア、2024年・2034年(%)
5.6 インスリン
5.6.1 2024〜2034年の地域別市場規模（US$ Billion）
5.6.2 地域別市場シェア、2024年・2034年(%)
5.7 ペプチドホルモン
5.7.1 2024〜2034年の地域別市場規模（US$ Billion）
5.7.2 地域別市場シェア、2024年・2034年(%)
5.8 ワクチン
5.8.1 2024〜2034年の地域別市場規模（US$ Billion）
5.8.2 地域別市場シェア、2024年・2034年(%)
5.9 免疫グロブリン
5.9.1 2024〜2034年の地域別市場規模（US$ Billion）
5.9.2 地域別市場シェア、2024年・2034年(%)
5.10 血液因子
5.10.1 2024〜2034年の地域別市場規模（US$ Billion）
5.10.2 地域別市場シェア、2024年・2034年(%)
5.11 ペプチド抗生物質
5.11.1 2024〜2034年の地域別市場規模（US$ Billion）
5.11.2 地域別市場シェア、2024年・2034年(%)
5.12 その他のタイプ
5.12.1 2024〜2034年の地域別市場規模（US$ Billion）
5.12.2 地域別市場シェア、2024年・2034年(%)

6 無菌注射薬の製造委託アウトソーシング（CMO）市場：用途別
6.1 主要調査結果
6.2 用途セグメント市場魅力度指数
6.3 無菌注射剤の製造委託アウトソーシング（CMO）の用途別市場規模推定と予測
6.4 癌
6.4.1 2024〜2034年の地域別市場規模（US$ Billion）
6.4.2 地域別市場シェア、2024年・2034年(%)
6.5 糖尿病
6.5.1 2024〜2034年の地域別市場規模（US$ Billion）
6.5.2 地域別市場シェア、2024年・2034年(%)
6.6 循環器疾患
6.6.1 2024〜2034年の地域別市場規模（US$ Billion）
6.6.2 地域別市場シェア、2024年・2034年(%)
6.7 中枢神経系疾患
6.7.1 2024〜2034年の地域別市場規模（US$ Billion）
6.7.2 地域別市場シェア、2024年・2034年(%)
6.8 感染症
6.8.1 2024〜2034年の地域別市場規模（US$ Billion）
6.8.2 地域別市場シェア、2024年・2034年(%)
6.9 その他
6.9.1 2024〜2034年の地域別市場規模（US$ Billion）
6.9.2 地域別市場シェア、2024年・2034年(%)

7 無菌注射薬の製造委託アウトソーシング（CMO）市場：容器タイプ別
7.1 主要調査結果
7.2 容器タイプセグメント市場魅力度指数
7.3 無菌注射薬の製造委託アウトソーシング（CMO）市場：容器タイプ別市場規模推定と予測
7.4 ボトル
7.4.1 2024〜2034年の地域別市場規模（US$ Billion）
7.4.2 地域別市場シェア、2024年・2034年(%)
7.5 アンプル
7.5.1 2024〜2034年の地域別市場規模（US$ Billion）
7.5.2 地域別市場シェア、2024年・2034年(%)
7.6 バイアル
7.6.1 2024〜2034年の地域別市場規模（US$ Billion）
7.6.2 地域別市場シェア、2024年・2034年(%)
7.7 プレフィルドシリンジ
7.7.1 2024〜2034年の地域別市場規模（US$ Billion）
7.7.2 地域別市場シェア、2024年・2034年(%)
7.8 バッグ
7.8.1 2024〜2034年の地域別市場規模（US$ Billion）
7.8.2 地域別市場シェア、2024年・2034年(%)

8 無菌注射薬の製造委託アウトソーシング（CMO）市場：投与経路別
8.1 主要調査結果
8.2 投与経路セグメント市場魅力度指数
8.3 無菌注射薬の製造委託アウトソーシング（CMO）：投与経路別市場規模推定と予測
8.4 皮下
8.4.1 2024〜2034年の地域別市場規模（US$ Billion）
8.4.2 地域別市場シェア、2024年・2034年(%)
8.5 静注
8.5.1 2024〜2034年の地域別市場規模（US$ Billion）
8.5.2 地域別市場シェア、2024年・2034年(%)
8.6 筋肉注射
8.6.1 2024〜2034年の地域別市場規模（US$ Billion）
8.6.2 地域別市場シェア、2024年・2034年(%)
8.7 その他の投与経路
8.7.1 2024〜2034年の地域別市場規模（US$ Billion）
8.7.2 地域別市場シェア、2024年・2034年(%)

9 無菌注射薬の製造委託アウトソーシング（CMO）市場：サービス別
9.1 主要調査結果
9.2 サービスセグメント市場魅力度指数
9.3 無菌注射薬の製造委託アウトソーシング（CMO）サービス別市場規模推定と予測
9.4 バイオ分析試験
9.4.1 2024〜2034年の地域別市場規模（US$ Billion）
9.4.2 地域別市場シェア、2024年・2034年(%)
9.5 メソッド開発とバリデーション
9.5.1 2024〜2034年の地域別市場規模（US$ Billion）
9.5.2 地域別市場シェア、2024年・2034年(%)
9.6 安定性試験
9.6.1 2024〜2034年の地域別市場規模（US$ Billion）
9.6.2 地域別市場シェア、2024年・2034年(%)
9.7 その他
9.7.1 2024〜2034年の地域別市場規模（US$ Billion）
9.7.2 地域別市場シェア、2024年・2034年(%)

10 無菌注射薬の製造委託アウトソーシング（CMO）市場分析：地域別
10.1 主要な調査結果
10.2 地域別市場規模の推定と予測

11 北米の無菌注射薬の製造委託アウトソーシング（CMO）市場分析
11.1 主要な調査結果
11.2 北米の無菌注射薬の製造委託アウトソーシング（CMO）市場魅力度指数
11.3 北米の無菌注射薬の製造委託アウトソーシング（CMO）国別市場、2024年、2029年、2034年（US$ Billion）
11.4 北米の無菌注射薬の製造委託アウトソーシング（CMO）市場規模推定と予測：国別
11.5 北米の無菌注射薬の製造委託アウトソーシング（CMO）市場規模推定と予測：分子タイプ別
11.6 北米の無菌注射薬の製造委託アウトソーシング（CMO）市場規模推定と予測：タイプ別
11.7 北米の無菌注射薬の製造委託アウトソーシング（CMO）市場規模推定と予測：用途別
11.8 北米の無菌注射薬の製造委託アウトソーシング（CMO）市場規模推定と予測：容器タイプ別
11.9 北米の無菌注射薬の製造委託アウトソーシング（CMO）市場規模推定と予測：投与経路別
11.10 北米の無菌注射薬の製造委託アウトソーシング（CMO）市場規模推定と予測：：サービス別
11.11 米国の無菌注射薬の製造委託アウトソーシング（CMO）市場分析
11.12 カナダの無菌注射薬の製造委託アウトソーシング（CMO）市場分析

12 欧州の無菌注射薬の製造委託アウトソーシング（CMO）市場分析
12.1 主要な調査結果
12.2 欧州の無菌注射薬の製造委託アウトソーシング（CMO）市場魅力度指数
12.3 欧州の無菌注射薬の製造委託アウトソーシング（CMO）国別市場、2024年、2029年、2034年（US$ Billion）
12.4 欧州の無菌注射薬の製造委託アウトソーシング（CMO）市場規模推定と予測：国別
12.5 欧州の無菌注射薬の製造委託アウトソーシング（CMO）市場規模推定と予測：分子タイプ別
12.6 欧州の無菌注射薬の製造委託アウトソーシング（CMO）市場規模推定と予測：タイプ別
12.7 欧州の無菌注射薬の製造委託アウトソーシング（CMO）市場規模推定と予測：用途別
12.8 欧州の無菌注射薬の製造委託アウトソーシング（CMO）市場規模推定と予測：容器タイプ別
12.9 欧州の無菌注射薬の製造委託アウトソーシング（CMO）市場規模推定と予測：投与経路別
12.10 欧州の無菌注射薬の製造委託アウトソーシング（CMO）市場規模推定と予測：サービス別
12.11 ドイツの無菌注射薬の製造委託アウトソーシング（CMO）市場分析
12.12 イギリスの無菌注射薬の製造委託アウトソーシング（CMO）市場分析
12.13 フランスの無菌注射薬の製造委託アウトソーシング（CMO）市場分析
12.14 イタリアの無菌注射薬の製造委託アウトソーシング（CMO）市場分析
12.15 スペインの無菌注射薬の製造委託アウトソーシング（CMO）市場分析
12.16 スイスの無菌注射薬の製造委託アウトソーシング（CMO）市場分析
12.17 オランダの無菌注射薬の製造委託アウトソーシング（CMO）市場分析
12.18 その他の欧州の無菌注射薬の製造委託アウトソーシング（CMO）市場分析

13 アジア太平洋地域の無菌注射薬の製造委託アウトソーシング（CMO）市場分析
13.1 主要な調査結果
13.2 アジア太平洋地域の無菌注射薬の製造委託アウトソーシング（CMO）市場魅力度指数
13.3 アジア太平洋地域の無菌注射薬の製造委託アウトソーシング（CMO）国別市場、2024年、2029年、2034年（US$ Billion）
13.4 アジア太平洋地域の無菌注射薬の製造委託アウトソーシング（CMO）市場規模推定と予測：国別
13.5 アジア太平洋地域の無菌注射薬の製造委託アウトソーシング（CMO）市場規模推定と予測：分子タイプ別
13.6 アジア太平洋地域の無菌注射薬の製造委託アウトソーシング（CMO）市場規模推定と予測：タイプ別
13.7 アジア太平洋地域の無菌注射薬の製造委託アウトソーシング（CMO）市場規模推定と予測：用途別
13.8 アジア太平洋地域の無菌注射薬の製造委託アウトソーシング（CMO）市場規模推定と予測：容器タイプ別
13.9 アジア太平洋地域の無菌注射薬の製造委託アウトソーシング（CMO）市場規模推定と予測：投与経路別
13.10 アジア太平洋地域の無菌注射薬の製造委託アウトソーシング（CMO）市場規模推定と予測：サービス別
13.11 日本の無菌注射薬の製造委託アウトソーシング（CMO）市場分析
13.12 中国の無菌注射薬の製造委託アウトソーシング（CMO）市場分析
13.13 インドの無菌注射薬の製造委託アウトソーシング（CMO）市場分析
13.14 オーストラリアの無菌注射薬の製造委託アウトソーシング（CMO）市場分析
13.15 韓国の無菌注射薬の製造委託アウトソーシング（CMO）市場分析
13.16 東南アジアの無菌注射薬の製造委託アウトソーシング（CMO）市場分析
13.17 その他のアジア太平洋地域の無菌注射薬の製造委託アウトソーシング（CMO）市場分析

14 ラテンアメリカの無菌注射薬の製造委託アウトソーシング（CMO）市場分析
14.1 主要な調査結果
14.2 ラテンアメリカの無菌注射薬の製造委託アウトソーシング（CMO）市場魅力度指数
14.3 ラテンアメリカの無菌注射薬の製造委託アウトソーシング（CMO）国別市場、2024年、2029年、2034年（US$ Billion)
14.4 ラテンアメリカの無菌注射薬の製造委託アウトソーシング（CMO）市場規模推定と予測：国別
14.5 ラテンアメリカの無菌注射薬の製造委託アウトソーシング（CMO）市場規模推定と予測：分子タイプ別
14.6 ラテンアメリカの無菌注射薬の製造委託アウトソーシング（CMO）市場規模推定と予測：タイプ別
14.7 ラテンアメリカの無菌注射薬の製造委託アウトソーシング（CMO）市場規模推定と予測：用途別
14.8 ラテンアメリカの無菌注射薬の製造委託アウトソーシング（CMO）市場規模推定と予測：容器タイプ別
14.9 ラテンアメリカの無菌注射薬の製造委託アウトソーシング（CMO）市場規模推定と予測：投与経路別
14.10 ラテンアメリカの無菌注射薬の製造委託アウトソーシング（CMO）市場規模推定と予測：サービス別
14.11 ブラジルの無菌注射薬の製造委託アウトソーシング（CMO）市場分析
14.12 メキシコの無菌注射薬の製造委託アウトソーシング（CMO）市場分析
14.13 アルゼンチンの無菌注射薬の製造委託アウトソーシング（CMO）市場分析
14.14 その他のラテンアメリカの無菌注射薬の製造委託アウトソーシング（CMO）市場分析

15 MEAの無菌注射薬の製造委託アウトソーシング（CMO）市場分析
15.1 主要な調査結果
15.2 MEAの無菌注射薬の製造委託アウトソーシング（CMO）市場魅力度指数
15.3 MEAの無菌注射薬の製造委託アウトソーシング（CMO）国別市場、2024年、2029年、2034年（10億米ドル）
15.4 MEAの無菌注射薬の製造委託アウトソーシング（CMO）市場規模推定と予測：国別
15.5 MEAの無菌注射薬の製造委託アウトソーシング（CMO）市場規模推定と予測：分子タイプ別
15.6 MEAの無菌注射薬の製造委託アウトソーシング（CMO）市場規模推定と予測：タイプ別
15.7 MEAの無菌注射薬の製造委託アウトソーシング（CMO）市場規模推定と予測：用途別
15.8 MEAの無菌注射薬の製造委託アウトソーシング（CMO）市場規模推定と予測：容器タイプ別
15.9 MEAの無菌注射薬の製造委託アウトソーシング（CMO）市場規模推定と予測：投与経路別
15.10 MEAの無菌注射薬の製造委託アウトソーシング（CMO）市場規模推定と予測：サービス別
15.11 GCCの無菌注射薬の製造委託アウトソーシング（CMO）市場分析
15.12 南アフリカの無菌注射薬の製造委託アウトソーシング（CMO）市場分析
15.13 エジプトの無菌注射薬の製造委託アウトソーシング（CMO）市場分析
15.14 その他のMEAの無菌注射薬の製造委託アウトソーシング（CMO）市場分析

16 会社概要
16.1 競争環境、2022年
16.2 Aenova Group
16.2.1 会社概要
16.2.2 会社概要
16.2.3 財務分析
16.2.3.1 純収入、2018-2022年
16.2.3.2 セグメント市場シェア、2022年
16.2.3.3 地域別市場シェア、2022年
16.2.4 サービスベンチマーク
16.2.5 戦略的展望
16.3 Almac Group
16.3.1 会社概要
16.3.2 会社概要
16.3.3 サービス・ベンチマーク
16.3.4 戦略的展望
16.4 WuXi AppTec
16.4.1 会社概要
16.4.2 会社概要
16.4.3 財務分析
16.4.3.1 純収入、2018-2022年
16.4.3.2 R＆D、2018-2022年
16.4.3.3 セグメント市場シェア、2022年
16.4.3.4 地域市場シェア、2022年
16.4.4 サービスベンチマーク
16.4.5 戦略的展望
16.5 Boehringer Ingelheim International GmbH
16.5.1 会社概要
16.5.2 会社概要
16.5.3 財務分析
16.5.3.1 純収入、2018-2022年
16.5.3.2 セグメント市場シェア、2022年
16.5.3.3 地域市場シェア、2022年
16.5.4 サービスベンチマーク
16.5.5 戦略的展望
16.6 Catalent, Inc.
16.6.1 会社概要
16.6.2 会社概要
16.6.3 財務分析
16.6.3.1 純収入、2018-2022年
16.6.3.2 セグメント市場シェア、2022年
16.6.3.3 地域市場シェア、2022年
16.6.4 サービスベンチマーク
16.6.5 戦略的展望
16.7 CordenPharma International
16.7.1 会社概要
16.7.2 会社概要
16.7.3 サービス・ベンチマーク
16.7.4 戦略的展望
16.8 Evonik Industries AG
16.8.1 会社概要
16.8.2 会社概要
16.8.3 財務分析
16.8.3.1 純収入、2018-2022年
16.8.3.2 R＆D、2018年〜2022年
16.8.3.3 セグメント市場シェア、2022年
16.8.3.4 地域市場シェア、2022年
16.8.4 サービスベンチマーク
16.8.5 戦略的展望
16.9 FAMAR Health Care Services
16.9.1 会社概要
16.9.2 会社概要
16.9.3 サービス・ベンチマーク
16.9.4 戦略的展望
16.10 Fresenius Kabi AG
16.10.1 会社概要
16.10.2 会社概要
16.10.3 財務分析
16.10.3.1 純収入、2018-2022年
16.10.3.2 R＆D、2018年～2022年
16.10.3.3 セグメント市場シェア、2022年
16.10.3.4 地域市場シェア、2022年
16.10.4 サービスベンチマーク
16.10.5 戦略的展望
16.11 Grifols, S.A.
16.11.1 会社概要
16.11.2 会社概要
16.11.3 財務分析
16.11.3.1 純収入、2018-2022年
16.11.3.2 R＆D、2018年～2022年
16.11.3.3 セグメント市場シェア、2022年
16.11.3.4 地域市場シェア、2022年
16.11.4 サービスベンチマーク
16.11.5 戦略的展望
16.12 Hikma Pharmaceuticals PLC
16.12.1 会社概要
16.12.2 会社概要
16.12.3 財務分析
16.12.3.1 純収入、2018-2022年
16.12.3.2 R＆D、2018-2022年
16.12.3.3 セグメント市場シェア、2022年
16.12.3.4 地域市場シェア、2022年
16.12.4 サービスベンチマーク
16.12.5 戦略的展望
16.13 Jubilant Pharmova Limited
16.13.1 会社概要
16.13.2 会社概要
16.13.3 財務分析
16.13.3.1 純収入、2018年～2022年
16.13.3.2 セグメント市場シェア、2022年
16.13.3.3 地域別市場シェア、2022年
16.13.4 サービスベンチマーク
16.13.5 戦略的展望
16.14 Lonza
16.14.1 会社概要
16.14.2 会社概要
16.14.3 財務分析
16.14.3.1 純収入、2018-2022年
16.14.3.2 R＆D、2018年〜2022年
16.14.3.3 セグメント市場シェア、2022年
16.14.3.4 地域市場シェア、2022年
16.14.4 サービスベンチマーク
16.14.5 戦略的展望
16.15 Patheon Pharma Services (Thermo Fisher Scientific Inc.)
16.15.1 会社概要
16.15.2 会社概要
16.15.3 財務分析
16.15.3.1 純収入、2018-2022年
16.15.3.2 R＆D、2018年〜2022年
16.15.3.3 セグメント市場シェア、2022年
16.15.3.4 地域市場シェア、2022年
16.15.4 サービスベンチマーク
16.15.5 戦略的展望
16.16 Pfizer Inc.
16.16.1 会社概要
16.16.2 会社概要
16.16.3 財務分析
16.16.3.1 純収入、2018-2022年
16.16.3.2 R＆D、2018年〜2022年
16.16.3.3 セグメント市場シェア、2022年
16.16.3.4 地域市場シェア、2022年
16.16.4 サービスベンチマーク
16.16.5 戦略的展望
16.17 Recipharm AB
16.17.1 会社概要
16.17.2 会社概要
16.17.3 財務分析
16.17.3.1 純収入、2018-2022年
16.17.4 サービスベンチマーク
16.17.5 戦略的展望
16.18 Siegfried Holding AG
16.18.1 会社概要
16.18.2 会社概要
16.18.3 財務分析
16.18.3.1 純収入、2018-2022年
16.18.3.2 R＆D、2018年～2022年
16.18.3.3 セグメント市場シェア、2022年
16.18.4 サービスベンチマーク
16.18.5 戦略的展望
16.19 Nexus Pharmaceuticals, LLC
16.19.1 会社概要
16.19.2 会社概要
16.19.3 サービス・ベンチマーク
16.19.4 戦略的展望
16.20 Avara Pharmaceutical Services, Inc.
16.20.1 会社概要
16.20.2 会社概要
16.20.3 サービス・ベンチマーク
16.21 Lilly
16.21.1 会社概要
16.21.2 会社概要
16.21.3 財務分析
16.21.3.1 純収入、2018-2022年
16.21.3.2 売上高、2018-2022年
16.21.3.3 地域市場シェア、2022年
16.21.4 サービスベンチマーク
16.21.5 戦略的展望
16.22 Adare Pharma Solutions
16.22.1 会社概要
16.22.2 会社概要
16.22.3 サービス・ベンチマーク
16.22.4 戦略的展望
16.23 Vetter Pharma
16.23.1 会社概要
16.23.2 会社概要
16.23.3 サービス・ベンチマーク
16.23.4 戦略的展望
16.24 Piramal Pharma Solutions
16.24.1 会社概要
16.24.2 会社概要
16.24.3 サービス・ベンチマーク
16.24.4 戦略的展望

17 結論と提言
17.1 Visiongainからの結びの言葉
17.2 市場プレイヤーへの提言

ページTOPに戻る

図表リスト

表の一覧
Table 1 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Snapshot, 2024 & 2034 (US$ Billion, CAGR %)
Table 2 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%): “V” Shaped Recovery
Table 3 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%): “U” Shaped Recovery
Table 4 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%): “W” Shaped Recovery
Table 5 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%): “L” Shaped Recovery
Table 6 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Molecule Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 7 Small Molecule Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 8 Large Molecule Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 9 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 10 Monoclonal Antibodies (mAbs) Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 11 Cytokines Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 12 Insulin Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 13 Peptide Hormones Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 14 Vaccines Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 15 Immunoglobulins Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 16 Blood Factor Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 17 Peptide Antibiotics Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 18 Other Type Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 19 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Application, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 20 Cancer Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 21 Diabetes Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 22 Cardiovascular Diseases Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 23 CNS Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 24 Infectious Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 25 Others Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 26 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Container Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 27 Bottles Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 28 AMPOULES Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 29 Vials Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 30 Prefilled Syringes Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 31 Bags Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 32 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 33 Subcutaneous Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 34 Intravenous Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 35 Intramuscular Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 36 Other Route of Administration Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 37 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Service, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 38 Bioanalytical Testing Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 39 Method Development & Validation Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 40 Stability Testing Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 41 Others Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 42 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 43 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 44 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Molecule Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 45 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 46 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Application, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 47 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Container Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 48 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 49 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Service, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 50 U.S. Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 51 Canada Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 52 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 53 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Molecule Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 54 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 55 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Application, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 56 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Container Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 57 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 58 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Service, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 59 Germany Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 60 UK Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 61 France Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 62 Italy Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 63 Spain Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 64 Switzerland Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 65 Netherlands Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 66 Rest of Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 67 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 68 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Molecule Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 69 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 70 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Application, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 71 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Container Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 72 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 73 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Service, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 74 Japan Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 75 China Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 76 India Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 77 Australia Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 78 South Korea Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 79 South East Asia Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 80 Rest of Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 81 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 82 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Molecule Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 83 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 84 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Application, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 85 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Container Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 86 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 87 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Service, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 88 Brazil Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 89 Mexico Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 90 Argentina Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 91 Rest of Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 92 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 93 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Molecule Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 94 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 95 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Application, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 96 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Container Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 97 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 98 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Service, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 99 GCC Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 100 South Africa Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 101 Egypt Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 102 Rest of MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 103 Aenova Group: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 104 Aenova Group: Service Benchmarking
Table 105 Aenova Group: Strategic Outlook
Table 106 Almac Group: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 107 Almac Group: Service Benchmarking
Table 108 Almac Group: Strategic Outlook
Table 109 WuXi AppTec : Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 110 WuXi AppTec : Service Benchmarking
Table 111 WuXi AppTec : Strategic Outlook
Table 112 Boehringer Ingelheim International GmbH: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 113 Boehringer Ingelheim International GmbH: Service Benchmarking
Table 114 Boehringer Ingelheim International GmbH: Strategic Outlook
Table 115 Catalent, Inc. : Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 116 Catalent, Inc. : Service Benchmarking
Table 117 Catalent, Inc. : Strategic Outlook
Table 118 CordenPharma International: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 119 CordenPharma International: Service Benchmarking
Table 120 CordenPharma International: Strategic Outlook
Table 121 Evonik Industries AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 122 Evonik Industries AG: Service Benchmarking
Table 123 Evonik Industries AG: Strategic Outlook
Table 124 FAMAR Health Care Services: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 125 FAMAR Health Care Services.: Service Benchmarking
Table 126 FAMAR Health Care Services.: Strategic Outlook
Table 127 Fresenius Kabi AG : Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 128 Fresenius Kabi AG: Service Benchmarking
Table 129 Fresenius Kabi AG: Strategic Outlook
Table 130 Grifols, S.A.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 131 Grifols, S.A.: Service Benchmarking
Table 132 Grifols, S.A.: Strategic Outlook
Table 133 Hikma Pharmaceuticals PLC: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 134 Hikma Pharmaceuticals PLC: Service Benchmarking
Table 135 Hikma Pharmaceuticals PLC: Strategic Outlook
Table 136 Jubilant Pharmova Limited : Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 137 Jubilant Pharmova Limited : Service Benchmarking
Table 138 Jubilant Pharmova Limited : Strategic Outlook
Table 139 Lonza : Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 140 Lonza: Service Benchmarking
Table 141 Lonza: Strategic Outlook
Table 142 Patheon Pharma Services (Thermo Fisher Scientific Inc.): Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 143 Patheon Pharma Services (Thermo Fisher Scientific Inc.): Service Benchmarking
Table 144 Patheon Pharma Services (Thermo Fisher Scientific inc.): Strategic Outlook
Table 145 Pfizer Inc. : Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 146 Pfizer Inc.: Service Benchmarking
Table 147 Pfizer Inc.: Strategic Outlook
Table 148 Recipharm AB : Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 149 Recipharm AB: Service Benchmarking
Table 150 Recipharm AB: Strategic Outlook
Table 151 Siegfried Holding AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 152 Siegfried Holding AG: Service Benchmarking
Table 153 Recipharm AB: Strategic Outlook
Table 154 Nexus Pharmaceuticals, LLC: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 155 Nexus Pharmaceuticals, LLC: Service Benchmarking
Table 156 Nexus Pharmaceuticals, LLC: Strategic Outlook
Table 157 Avara Pharmaceutical Services, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 158 Avara Pharmaceutical Services, Inc.: Service Benchmarking
Table 159 Lilly: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 160 Lilly: Service Benchmarking
Table 161 Lilly: Strategic Outlook
Table 162 Adare Pharma Solutions.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 163 Adare Pharma Solutions.: Service Benchmarking
Table 164 Adare Pharma Solutions.: Strategic Outlook
Table 165 Vetter Pharma: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 166 Vetter Pharma: Service Benchmarking
Table 167 Vetter Pharma: Strategic Outlook
Table 168 Piramal Pharma Solutions: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 169 Piramal Pharma Solutions: Service Benchmarking
Table 170 Piramal Pharma Solutions: Strategic Outlook

図の一覧
Figure 1 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Segmentation
Figure 2 Contract Manufacturing Outsourcing (CMO) Market Attractiveness Index by Region
Figure 3 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Molecule Type: Market Attractiveness Index
Figure 4 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Type: Market Attractiveness Index
Figure 5 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Application: Market Attractiveness Index
Figure 6 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Container Type: Market Attractiveness Index
Figure 7 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Route of Administration: Market Attractiveness Index
Figure 8 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Service: Market Attractiveness Index
Figure 9 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market: Market Dynamics
Figure 10 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Region, 2024-2034 (US$ Billion, AGR %): “V” Shaped Recovery
Figure 11 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Region, 2024-2034 (US$ Billion, AGR %): “U” Shaped Recovery
Figure 12 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Region, 2024-2034 (US$ Billion, AGR %): “W” Shaped Recovery
Figure 13 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Region, 2024-2034 (US$ Billion, AGR %): “L” Shaped Recovery
Figure 14 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market: Porter’s Five Forces Analysis
Figure 15 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market: SWOT Analysis
Figure 16 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market: PEST Analysis
Figure 17 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Molecule Type: Market Attractiveness Index
Figure 18 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Molecule Type, 2024-2034 (US$ Billion, AGR %)
Figure 19 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Molecule Type, 2024, 2029, 2034 (%)
Figure 20 Small Molecule Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 21 Small Molecule Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 22 Large Molecule Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 23 Large Molecule Market Share Forecast by Region, 2024 & 2034 (%)
Figure 24 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Type: Market Attractiveness Index
Figure 25 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Type, 2024-2034 (US$ Billion)
Figure 26 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Type, 2024, 2029, 2034 (%)
Figure 27 Monoclonal Antibodies (mAbs) Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 28 Monoclonal Antibodies (mAbs) Market Share Forecast by Region, 2024 & 2034 (%)
Figure 29 Cytokines Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 30 Cytokines Market Share Forecast by Region, 2024 & 2034 (%)
Figure 31 Insulin Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 32 Insulin Market Share Forecast by Region, 2024 & 2034 (%)
Figure 33 Peptide Hormones Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 34 Peptide Hormones Market Share Forecast by Region, 2024 & 2034 (%)
Figure 35 Vaccines Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 36 Vaccines Market Share Forecast by Region, 2024 & 2034 (%)
Figure 37 Immunoglobulins Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 38 Immunoglobulins Market Share Forecast by Region, 2024 & 2034 (%)
Figure 39 Blood Factor Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 40 Blood Factor Market Share Forecast by Region, 2024 & 2034 (%)
Figure 41 Peptide Antibiotics Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 42 Peptide Antibiotics Market Share Forecast by Region, 2024 & 2034 (%)
Figure 43 Other Type Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 44 Other Type Market Share Forecast by Region, 2024 & 2034 (%)
Figure 45 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Application: Market Attractiveness Index
Figure 46 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Application, 2024-2034 (US$ Billion)
Figure 47 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Application, 2024, 2029, 2034 (%)
Figure 48 Cancer Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 49 Cancer Market Share Forecast by Region, 2024 & 2034 (%)
Figure 50 Diabetes Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 51 Diabetes Market Share Forecast by Region, 2024 & 2034 (%)
Figure 52 Cardiovascular Diseases Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 53 Cardiovascular Diseases Market Share Forecast by Region, 2024 & 2034 (%)
Figure 54 CNS Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 55 CNS Market Share Forecast by Region, 2024 & 2034 (%)
Figure 56 Infectious Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 57 Infectious Market Share Forecast by Region, 2024 & 2034 (%)
Figure 58 Others Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 59 Others Market Share Forecast by Region, 2024 & 2034 (%)
Figure 60 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Container Type: Market Attractiveness Index
Figure 61 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Container Type, 2024-2034 (US$ Billion)
Figure 62 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Container Type, 2024, 2029, 2034 (%)
Figure 63 Bottles Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 64 Bottles Market Share Forecast by Region, 2024 & 2034 (%)
Figure 65 AMPOULES Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 66 AMPOULES Market Share Forecast by Region, 2024 & 2034 (%)
Figure 67 Vials Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 68 Vials Market Share Forecast by Region, 2024 & 2034 (%)
Figure 69 Prefilled Syringes Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 70 Prefilled Syringes Market Share Forecast by Region, 2024 & 2034 (%)
Figure 71 Bags Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 72 Bags Market Share Forecast by Region, 2024 & 2034 (%)
Figure 73 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Route of Administration: Market Attractiveness Index
Figure 74 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion)
Figure 75 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Route of Administration, 2024, 2029, 2034 (%)
Figure 76 Subcutaneous Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 77 Subcutaneous Market Share Forecast by Region, 2024 & 2034 (%)
Figure 78 Intravenous Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 79 Intravenous Market Share Forecast by Region, 2024 & 2034 (%)
Figure 80 Intramuscular Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 81 Intramuscular Market Share Forecast by Region, 2024 & 2034 (%)
Figure 82 Other Route of Administration Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 83 Other Route of Administration Market Share Forecast by Region, 2024 & 2034 (%)
Figure 84 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Service: Market Attractiveness Index
Figure 85 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Service, 2024-2034 (US$ Billion)
Figure 86 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Service, 2024, 2029, 2034 (%)
Figure 87 Bioanalytical Testing Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 88 Bioanalytical Testing Market Share Forecast by Region, 2024 & 2034 (%)
Figure 89 Method Development & Validation Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 90 Method Development & Validation Market Share Forecast by Region, 2024 & 2034 (%)
Figure 91 Stability Testing Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 92 Stability Testing Market Share Forecast by Region, 2024 & 2034 (%)
Figure 93 Others Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 94 Others Market Share Forecast by Region, 2024 & 2034 (%)
Figure 95 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Region 2024 and 2034 (Revenue, CAGR%)
Figure 96 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Region 2024, 2029, 2034 (%)
Figure 97 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Region, 2024-2034 (US$ Billion, AGR %)
Figure 98 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Attractiveness Index
Figure 99 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 100 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
Figure 101 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Country, 2024 & 2034 (%)
Figure 102 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Molecule Type, 2024-2034 (US$ Billion, AGR %)
Figure 103 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Molecule Type, 2024 & 2034 (%)
Figure 104 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR %)
Figure 105 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Type, 2024 & 2034 (%)
Figure 106 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Application, 2024-2034 (US$ Billion, AGR %)
Figure 107 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Application, 2024 & 2034 (%)
Figure 108 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Container Type, 2024-2034 (US$ Billion, AGR %)
Figure 109 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Container Type, 2024 & 2034 (%)
Figure 110 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR %)
Figure 111 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Route of Administration, 2024 & 2034 (%)
Figure 112 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Service, 2024-2034 (US$ Billion, AGR %)
Figure 113 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Service, 2024 & 2034 (%)
Figure 114 U.S. Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 115 Canada Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 116 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Attractiveness Index
Figure 117 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 118 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Country, 2024-2034 (US$ Billion)
Figure 119 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Country, 2024 & 2034 (%)
Figure 120 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Molecule Type, 2024-2034 (US$ Billion)
Figure 121 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Molecule Type, 2024 & 2034 (%)
Figure 122 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Type, 2024-2034 (US$ Billion)
Figure 123 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Type, 2024 & 2034 (%)
Figure 124 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Application, 2024-2034 (US$ Billion)
Figure 125 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Application, 2024 & 2034(%)
Figure 126 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Container Type, 2024-2034 (US$ Billion)
Figure 127 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Container Type, 2024 & 2034(%)
Figure 128 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion)
Figure 129 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Route of Administration, 2024 & 2034(%)
Figure 130 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Service, 2024-2034 (US$ Billion)
Figure 131 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Service, 2024 & 2034(%)
Figure 132 Germany Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 133 UK Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 134 France Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 135 Italy Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 136 Spain Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 137 Switzerland Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 138 Netherlands Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 139 Rest of Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 140 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Attractiveness Index
Figure 141 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 142 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Country, 2024-2034 (US$ Billion)
Figure 143 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Country, 2024 & 2034 (%)
Figure 144 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Molecule Type, 2024-2034 (US$ Billion)
Figure 145 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Molecule Type, 2024 & 2034 (%)
Figure 146 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Type, 2024-2034 (US$ Billion)
Figure 147 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Type, 2024 & 2034 (%)
Figure 148 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Application, 2024-2034 (US$ Billion)
Figure 149 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Application, 2024 & 2034 (%)
Figure 150 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Container Type, 2024-2034 (US$ Billion)
Figure 151 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Container Type, 2024 & 2034 (%)
Figure 152 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion)
Figure 153 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Route of Administration, 2024 & 2034 (%)
Figure 154 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Service, 2024-2034 (US$ Billion)
Figure 155 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Service, 2024 & 2034 (%)
Figure 156 Japan Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 157 China Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 158 India Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 159 Australia Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 160 South Korea Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 161 South East Asia Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 162 Rest of Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 163 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Attractiveness Index
Figure 164 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 165 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Country, 2024-2034 (US$ Billion)
Figure 166 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Country, 2024 & 2034 (%)
Figure 167 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Molecule Type, 2024-2034 (US$ Billion)
Figure 168 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Molecule Type, 2024 & 2034 (%)
Figure 169 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Type, 2024-2034 (US$ Billion)
Figure 170 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Type, 2024 & 2034 (%)
Figure 171 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Application, 2024-2034 (US$ Billion)
Figure 172 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Application, 2024 & 2034 (%)
Figure 173 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Container Type, 2024-2034 (US$ Billion)
Figure 174 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Container Type, 2024 & 2034 (%)
Figure 175 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion)
Figure 176 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Route of Administration, 2024 & 2034 (%)
Figure 177 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Service, 2024-2034 (US$ Billion)
Figure 178 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Service, 2024 & 2034 (%)
Figure 179 Brazil Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 180 Mexico Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 181 Argentina Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 182 Rest of Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 183 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Attractiveness Index
Figure 184 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 185 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Country, 2024-2034 (US$ Billion)
Figure 186 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Country, 2024 & 2034 (%)
Figure 187 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Molecule Type, 2024-2034 (US$ Billion)
Figure 188 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Molecule Type, 2024 & 2034 (%)
Figure 189 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Type, 2024-2034 (US$ Billion)
Figure 190 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Type, 2024 & 2034 (%)
Figure 191 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Application, 2024-2034 (US$ Billion)
Figure 192 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Application, 2024 & 2034 (%)
Figure 193 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Container Type, 2024-2034 (US$ Billion)
Figure 194 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Container Type, 2024 & 2034 (%)
Figure 195 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion)
Figure 196 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Route of Administration, 2024 & 2034 (%)
Figure 197 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Service, 2024-2034 (US$ Billion)
Figure 198 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Service, 2024 & 2034 (%)
Figure 199 GCC Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 200 South Africa Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 201 Egypt Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 202 Rest of MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 203 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market: Company Share/Ranking, 2022
Figure 204 Aenova Group: Net Revenue, 2018-2022 (US$ Million, AGR %)
Figure 205 Aenova Group: Segment Market Shares, 2022
Figure 206 Aenova Group: Regional Market Shares, 2022
Figure 207 WuXi AppTec : Net Revenue, 2018-2022 (US$ Million, AGR %)
Figure 208 WuXi AppTec : R&D, 2018-2022 (US$ Million, AGR %)
Figure 209 WuXi AppTec : Segment Market Shares, 2022
Figure 210 WuXi AppTec : Regional Market Shares, 2022
Figure 211 Boehringer Ingelheim International GmbH: Net Revenue, 2018-2022 (US$ Million, AGR %)
Figure 212 Boehringer Ingelheim International GmbH: Segment Market Shares, 2022
Figure 213 Boehringer Ingelheim International GmbH: Regional Market Shares, 2022
Figure 214 Catalent, Inc. : Net Revenue, 2018-2022 (US$ Million, AGR (%)
Figure 215 Catalent, Inc. : Segment Market Shares, 2022
Figure 216 Catalent, Inc. : Regional Market Shares, 2022
Figure 217 Evonik Industries AG: Net Revenue, 2018-2022 (US$ Million, AGR %)
Figure 218 Evonik Industries AG: R&D, 2018-2022 (US$ Million, AGR %)
Figure 219 Evonik Industries AG: Segment Market Shares, 2022
Figure 220 Evonik Industries AG: Regional Market Shares, 2022
Figure 221 Fresenius Kabi AG: Net Revenue, 2018-2022 (US$ Million, AGR %)
Figure 222 Fresenius Kabi AG: R&D, 2018-2022 (US$ Million, AGR %)
Figure 223 Fresenius Kabi AG: Segment Market Shares, 2022
Figure 224 Fresenius Kabi AG: Regional Market Shares, 2022
Figure 225 Grifols, S.A. : Net Revenue, 2018-2022 (US$ Million, AGR %)
Figure 226 Grifols, S.A.: R&D, 2018-2022 (US$ Million, AGR %)
Figure 227 Grifols, S.A.: Segment Market Shares, 2022
Figure 228 Grifols, S.A.: Regional Market Shares, 2022
Figure 229 Hikma Pharmaceuticals Plc: Net Revenue, 2018-2022 (US$ Million, AGR %)
Figure 230 Hikma Pharmaceuticals Plc: R&D, 2018-2022 (US$ Million, AGR %)
Figure 231 Hikma Pharmaceuticals Plc: Segment Market Shares, 2022
Figure 232 Hikma Pharmaceuticals Plc: Regional Market Shares, 2022
Figure 233 Jubilant Pharmova Limited: Net Revenue, 2018-2022 (US$ Million, AGR %)
Figure 234 Jubilant Pharmova Limited : Segment Market Shares, 2022
Figure 235 Jubilant Pharmova Limited .: Regional Market Shares, 2022
Figure 236 Lonza : Net Revenue, 2018-2022 (US$ Million, AGR %)
Figure 237 Lonza : R&D, 2018-2022 (US$ Million, AGR %)
Figure 238 Lonza : Segment Market Shares, 2022
Figure 239 Lonza : Regional Market Shares, 2022
Figure 240 Patheon Pharma Services (Thermo Fisher Scientific Inc.): Net Revenue, 2018-2022 (US$ Million, AGR %)
Figure 241 Patheon Pharma Services (Thermo Fisher Scientific Inc.): R&D, 2018-2022 (US$ Million, AGR %)
Figure 242 Patheon Pharma Services (Thermo Fisher Scientific Inc.): Segment Market Shares, 2022
Figure 243 Patheon Pharma Services (Thermo Fisher Scientific Inc.): Regional Market Shares, 2022
Figure 244 Pfizer Inc. : Net Revenue, 2018-2022 (US$ Million, AGR %)
Figure 245 Pfizer Inc.: R&D, 2018-2022 (US$ Million, AGR %)
Figure 246 Pfizer Inc.: Segment Market Shares, 2022
Figure 247 Pfizer Inc.: Regional Market Shares, 2022
Figure 248 Recipharm AB: Net Revenue, 2018-2022 (US$ Million, AGR %)
Figure 249 Siegfried Holding AG: Net Revenue, 2018-2022 (US$ Million, AGR %)
Figure 250 Siegfried Holding AG: R&D, 2018-2022 (US$ Million, AGR %)
Figure 251 Siegfried Holding AG: Segment Market Shares, 2022
Figure 252 Lilly: Net Revenue, 2018-2022 (US$ Million, AGR %)
Figure 253 Lilly: R&D, 2018-2022 (US$ Million, AGR %)
Figure 254 Lilly: Regional Market Shares, 2022

ページTOPに戻る

Table of Contents
List of Tables/Graphs

Summary

Report Details

The Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Increasing Investments in Pharmaceutical R&D and Increasing Demand for Biological are Driving the Market Growth
Research is substantially funded in the pharmaceutical industry, with forward-thinking businesses allocating 15% of their sales on average to R&D. Due to a growth in R&D investment on early-stage development and the volume of potential drugs at the preclinical stage, preclinical services are also in high demand among life science firms.Many pharmaceutical companies have increased their R&D spending to help with the development of new medicines and therapies. In 2022, the largest pharmaceutical firms, including Roche, Pfizer, Merck, and Bristol-Myers Squibb, would devote about one-fifth of their annual revenue to R&D efforts. As a result of the surge in pharmaceutical R&D spending, it is projected that the need for Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs will expand, providing CMOs with more opportunities to provide outsourcing services.

As a result, many people have investigated cost-cutting options, like outsourcing manufacturing. As more patents are slated to expire, more efforts are being made to uncover biologics and novel chemicals, and the expense of R&D is rising, drug makers and sponsors are under greater pressure to make up for the financial losses brought on by generics. This is making drug research even more expensive and complex. Even government organisations are turning to CROs to outsource their clinical production in order to have access to the necessary tools and expertise, as well as to cut costs and outsourcing timelines.

High Operational Costs Likely to Challenge Industry Growth
The high operational costs are impeding the rise of global revenue. Use of advanced equipment is necessary while producing sterile medications. For instance, a biotechnology business may need to create 3,000 vials of an injectable medicine (sterile fill and finish) in order to carry out a phase I–II clinical study in oncology. The projected costs to manufacture pharmaceutical items are as follows: project planning & management: $35,000; supplier management: $4,000; and drug product analytical development: $40,000. It is believed that the biotechnology company will assign the production task to a different contract drug manufacturing organization (CDMO). Furthermore, due to FDA requirements mandating extreme attention be taken in the manufacturing, packaging, storage, and distribution of sterile injectable pharmaceuticals, the operational cost burden is significant, which can hamper the CMO market growth.

What Questions Should You Ask Before Buying a Market Research Report?
• How is the Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs market evolving?
• What is driving and restraining the Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs market?
• How will each point of care diagnostic submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?
• How will the market shares for each Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs submarket develop from 2024 to 2034?
• What will be the main driver for the overall market from 2024 to 2034?
• Will leading Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?
• Who are the leading players and what are their prospects over the forecast period?
• What are the Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs projects for these leading companies?
• How will the industry evolve during the period between 2024 and 2034? What are the implications of Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs market?
• Where is the Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs market today, and over the next 10 years:
• Our 428-page report provides 170 tables, 254 charts, and graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2034 and other analyses reveal commercial prospects
• In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.

Segments Covered in the Report

Molecule Type
• Small Molecules
• Large Molecules

Type
• Monoclonal Antibodies
• Cytokines
• Insulin
• Peptide Hormones
• Vaccines
• Immunoglobulins
• Blood Factors
• Peptide Antibiotics
• Other Types

Application
• Cancer
• Diabetes
• Cardiovascular diseases
• CNS
• Infectious
• Others

Container Type
• Bottles
• Ampoules
• Vials
• Prefilled syringes
• Bags

Route of Administration
• Subcutaneous
• Intravenous
• Intramuscular
• Other Route of Administration

Service
• Bioanalytical Testing
• Method Development & Validation
• Stability Testing
• Others

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 18 leading national markets:

North America
• U.S.
• Canada

Europe
• Germany
• UK
• France
• Italy
• Spain
• Switzerland
• Netherlands
• Rest of Europe

Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• South East Asia
• Rest of Asia Pacific

Latin America
• Brazil
• Mexico
• Argentina
• Rest of Latin America

MEA
• GCC
• South Africa
• Egypt
• Rest of MEA

The report also includes profiles and for some of the leading companies in the Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market, 2024 to 2034, with a focus on this segment of these companies’ operations.

Leading companies and the potential for market growth
• Adare Pharma Solutions
• Aenova Group
• Almac Group
• Avara Pharmaceutical Services, Inc.
• Boehringer Ingelheim International GmbH
• Catalent, Inc.
• CordenPharma International
• Evonik Industries AG
• F. Hoffmann-La Roche Ltd.
• FAMAR Health Care Services
• Fresenius Kabi AG
• Grifols, S.A.
• Hikma Pharmaceuticals PLC
• Jubilant Pharmova Limited
• Lilly
• Lonza
• Nexus Pharmaceuticals, LLC
• Patheon Pharma Services (Thermo Fisher Scientific Inc.)
• Pfizer Inc.
• Piramal Pharma Solutions
• Recipharm AB
• Siegfried Holding AG
• Vetter Pharma
• Wuxi AppTec

Overall world revenue for Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market, 2024 to 2034 in terms of value the market will surpass US$24.2 billion in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market, 2024 to 2034 report help you?
In summary, our 420+ page report provides you with the following knowledge:

• Revenue forecasts to 2034 for Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs market, with forecasts for type, molecule type, application, container type, route of administration, services, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.

• Revenue forecasts to 2034 for five regional and 21 key national markets – See forecasts for the Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market, 2024 to 2034 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, Spain, Switzerland, Netherlands, China, India, Japan, Australia, South Korea, South East Asia, Argentina, GCC, South Africa, and Egypt among other prominent economies.

• Prospects for established firms and those seeking to enter the market – including company profiles for 25 of the major companies involved in the Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market, 2024 to 2034.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.

ページTOPに戻る

Table of Contents

1 Report Overview
1.1 Objectives of the Study
1.2 Introduction to CMO of Sterile Injectable Drugs Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report for?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain

2 Executive Summary

3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.2.1 Market Driving Factors
3.2.1.1 Growing Focus on Development to Treat Cancer
3.2.1.2 Rising Prevalence of Chronic Diseases
3.2.1.3 Rapid FDA Approvals of Sterile Injectable Drugs to Fuel Market Growth
3.2.1.4 As Manufacturers Invest in New Manufacturing Facilities, The Demand for Sterile Injectable is expected to Rise
3.2.1.5 Increasing Demand for Biological is Expected to Drive the Demand
3.2.1.6 Increasing Investments in Pharmaceutical R&D
3.2.2 Market Restraining Factors
3.2.2.1 Growing Competition from Small Manufacturers
3.2.2.2 High Operational Costs
3.2.2.3 Inadequate Healthcare Infrastructure Across Developing Economies Challenging Market Growth
3.2.3 Market Opportunities
3.2.3.1 Prefilled Syringes to Offer Lucrative Growth Prospects
3.2.3.2 Growing Investments
3.2.3.3 Expanding Clinical Trial Opportunities in the Asia Pacific Region
3.3 COVID-19 Impact Analysis
3.4 Porter’s Five Forces Analysis
3.4.1 Competitive Rivalry
3.4.2 Threat of New Entrants
3.4.3 Threat of Substitutes
3.4.4 Bargaining Power of Buyers
3.4.5 Bargaining Power of Suppliers
3.5 SWOT Analysis
3.6 PEST Analysis
3.6.1 Political Factors Impacting CMO of Sterile Injectable Drugs Market
3.6.2 Economic Factors Impacting CMO of Sterile Injectable Drugs Market
3.6.3 Social Factors Impacting CMO of Sterile Injectable Drugs Market
3.6.4 Technological Factors Impacting CMO of Sterile Injectable Drugs Market

4 CMO of Sterile Injectable Drugs Market Analysis by Molecule Type
4.1 Key Findings
4.2 Molecule Type Segment: Market Attractiveness Index
4.3 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Molecule Type
4.4 Small Molecule
4.4.1 Market Size by Region, 2024-2034 (US$ Billion)
4.4.2 Market Share by Region, 2024 & 2034 (%)
4.5 Large Molecule
4.5.1 Market Size by Region, 2024-2034 (US$ Billion)
4.5.2 Market Share by Region, 2024 & 2034 (%)

5 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market, by Type, 2024-2034
5.1 Key Findings
5.2 Type Segment: Market Attractiveness Index
5.3 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market, by Type
5.4 Monoclonal Antibodies (mAbs)
5.4.1 Market Size by Region, 2024-2034 (US$ Billion)
5.4.2 Market Share by Region, 2024 & 2034 (%)
5.5 Cytokines
5.5.1 Market Size by Region, 2024-2034 (US$ Billion)
5.5.2 Market Share by Region, 2024 & 2034 (%)
5.6 Insulin
5.6.1 Market Size by Region, 2024-2034 (US$ Billion)
5.6.2 Market Share by Region, 2024 & 2034 (%)
5.7 Peptide Hormones
5.7.1 Market Size by Region, 2024-2034 (US$ Billion)
5.7.2 Market Share by Region, 2024 & 2034 (%)
5.8 Vaccines
5.8.1 Market Size by Region, 2024-2034 (US$ Billion)
5.8.2 Market Share by Region, 2024 & 2034 (%)
5.9 Immunoglobulins
5.9.1 Market Size by Region, 2024-2034 (US$ Billion)
5.9.2 Market Share by Region, 2024 & 2034 (%)
5.10 Blood Factor
5.10.1 Market Size by Region, 2024-2034 (US$ Billion)
5.10.2 Market Share by Region, 2024 & 2034 (%)
5.11 Peptide Antibiotics
5.11.1 Market Size by Region, 2024-2034 (US$ Billion)
5.11.2 Market Share by Region, 2024 & 2034 (%)
5.12 Other Type
5.12.1 Market Size by Region, 2024-2034 (US$ Billion)
5.12.2 Market Share by Region, 2024 & 2034 (%)

6 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Application
6.1 Key Findings
6.2 Application Segment: Market Attractiveness Index
6.3 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Application
6.4 Cancer
6.4.1 Market Size by Region, 2024-2034 (US$ Billion)
6.4.2 Market Share by Region, 2024 & 2034 (%)
6.5 Diabetes
6.5.1 Market Size by Region, 2024-2034 (US$ Billion)
6.5.2 Market Share by Region, 2024 & 2034 (%)
6.6 Cardiovascular Diseases
6.6.1 Market Size by Region, 2024-2034 (US$ Billion)
6.6.2 Market Share by Region, 2024 & 2034 (%)
6.7 CNS
6.7.1 Market Size by Region, 2024-2034 (US$ Billion)
6.7.2 Market Share by Region, 2024 & 2034 (%)
6.8 Infectious
6.8.1 Market Size by Region, 2024-2034 (US$ Billion)
6.8.2 Market Share by Region, 2024 & 2034 (%)
6.9 Others
6.9.1 Market Size by Region, 2024-2034 (US$ Billion)
6.9.2 Market Share by Region, 2024 & 2034 (%)

7 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Container Type
7.1 Key Findings
7.2 Container Type Segment: Market Attractiveness Index
7.3 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Container Type
7.4 Bottles
7.4.1 Market Size by Region, 2024-2034 (US$ Billion)
7.4.2 Market Share by Region, 2024 & 2034 (%)
7.5 Ampoules
7.5.1 Market Size by Region, 2024-2034 (US$ Billion)
7.5.2 Market Share by Region, 2024 & 2034 (%)
7.6 Vials
7.6.1 Market Size by Region, 2024-2034 (US$ Billion)
7.6.2 Market Share by Region, 2024 & 2034 (%)
7.7 Prefilled Syringes
7.7.1 Market Size by Region, 2024-2034 (US$ Billion)
7.7.2 Market Share by Region, 2024 & 2034 (%)
7.8 Bags
7.8.1 Market Size by Region, 2024-2034 (US$ Billion)
7.8.2 Market Share by Region, 2024 & 2034 (%)

8 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Route of Administration
8.1 Key Findings
8.2 Route of Administration Segment: Market Attractiveness Index
8.3 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Route of Administration
8.4 Subcutaneous
8.4.1 Market Size by Region, 2024-2034 (US$ Billion)
8.4.2 Market Share by Region, 2024 & 2034 (%)
8.5 Intravenous
8.5.1 Market Size by Region, 2024-2034 (US$ Billion)
8.5.2 Market Share by Region, 2024 & 2034 (%)
8.6 Intramuscular
8.6.1 Market Size by Region, 2024-2034 (US$ Billion)
8.6.2 Market Share by Region, 2024 & 2034 (%)
8.7 Other Route of Administration
8.7.1 Market Size by Region, 2024-2034 (US$ Billion)
8.7.2 Market Share by Region, 2024 & 2034 (%)

9 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Service
9.1 Key Findings
9.2 Service Segment: Market Attractiveness Index
9.3 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Service
9.4 Bioanalytical Testing
9.4.1 Market Size by Region, 2024-2034 (US$ Billion)
9.4.2 Market Share by Region, 2024 & 2034 (%)
9.5 Method Development & Validation
9.5.1 Market Size by Region, 2024-2034 (US$ Billion)
9.5.2 Market Share by Region, 2024 & 2034 (%)
9.6 Stability Testing
9.6.1 Market Size by Region, 2024-2034 (US$ Billion)
9.6.2 Market Share by Region, 2024 & 2034 (%)
9.7 Others
9.7.1 Market Size by Region, 2024-2034 (US$ Billion)
9.7.2 Market Share by Region, 2024 & 2034 (%)

10 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis by Region
10.1 Key Findings
10.2 Regional Market Size Estimation and Forecast

11 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
11.1 Key Findings
11.2 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Attractiveness Index
11.3 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Country, 2024, 2029 & 2034 (US$ Billion)
11.4 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Country
11.5 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Molecule Type
11.6 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Type
11.7 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Application
11.8 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Container Type
11.9 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Route of Administration
11.10 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Service
11.11 U.S. Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
11.12 Canada Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis

12 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
12.1 Key Findings
12.2 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Attractiveness Index
12.3 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Country, 2024, 2029 & 2034 (US$ Billion)
12.4 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Country
12.5 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Molecule Type
12.6 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Type
12.7 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Application
12.8 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Container Type
12.9 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Route of Administration
12.10 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Service
12.11 Germany Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
12.12 UK Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
12.13 France Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
12.14 Italy Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
12.15 Spain Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
12.16 Switzerland Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
12.17 Netherlands Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
12.18 Rest of Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis

13 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
13.1 Key Findings
13.2 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Attractiveness Index
13.3 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Country, 2024, 2029 & 2034 (US$ Billion)
13.4 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Country
13.5 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Molecule Type
13.6 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Type
13.7 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Application
13.8 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Container Type
13.9 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Route of Administration
13.10 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Service
13.11 Japan Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
13.12 China Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
13.13 India Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
13.14 Australia Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
13.15 South Korea Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
13.16 South East Asia Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
13.17 Rest of Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis

14 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
14.1 Key Findings
14.2 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Attractiveness Index
14.3 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Country, 2024, 2029 & 2034 (US$ Billion)
14.4 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Country
14.5 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Molecule Type
14.6 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Type
14.7 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Application
14.8 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Container Type
14.9 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Route of Administration
14.10 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Service
14.11 Brazil Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
14.12 Mexico Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
14.13 Argentina Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
14.14 Rest of Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis

15 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
15.1 Key Findings
15.2 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Attractiveness Index
15.3 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Country, 2024, 2029 & 2034 (US$ Billion)
15.4 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Country
15.5 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Molecule Type
15.6 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Type
15.7 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Application
15.8 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Container Type
15.9 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Route of Administration
15.10 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Service
15.11 GCC Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
15.12 South Africa Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
15.13 Egypt Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
15.14 Rest of MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis

16 Company Profiles
16.1 Competitive Landscape, 2022
16.2 Aenova Group
16.2.1 Company Snapshot
16.2.2 Company Overview
16.2.3 Financial Analysis
16.2.3.1 Net Revenue, 2018-2022
16.2.3.2 Segment Market Shares, 2022
16.2.3.3 Regional Market Shares, 2022
16.2.4 Service Benchmarking
16.2.5 Strategic Outlook
16.3 Almac Group
16.3.1 Company Snapshot
16.3.2 Company Overview
16.3.3 Service Benchmarking
16.3.4 Strategic Outlook
16.4 WuXi AppTec
16.4.1 Company Snapshot
16.4.2 Company Overview
16.4.3 Financial Analysis
16.4.3.1 Net Revenue, 2018-2022
16.4.3.2 R&D, 2018-2022
16.4.3.3 Segment Market Shares, 2022
16.4.3.4 Regional Market Shares, 2022
16.4.4 Service Benchmarking
16.4.5 Strategic Outlook
16.5 Boehringer Ingelheim International GmbH
16.5.1 Company Snapshot
16.5.2 Company Overview
16.5.3 Financial Analysis
16.5.3.1 Net Revenue, 2018-2022
16.5.3.2 Segment Market Shares, 2022
16.5.3.3 Regional Market Shares, 2022
16.5.4 Service Benchmarking
16.5.5 Strategic Outlook
16.6 Catalent, Inc.
16.6.1 Company Snapshot
16.6.2 Company Overview
16.6.3 Financial Analysis
16.6.3.1 Net Revenue, 2018-2022
16.6.3.2 Segment Market Shares, 2022
16.6.3.3 Regional Market Shares, 2022
16.6.4 Service Benchmarking
16.6.5 Strategic Outlook
16.7 CordenPharma International
16.7.1 Company Snapshot
16.7.2 Company Overview
16.7.3 Service Benchmarking
16.7.4 Strategic Outlook
16.8 Evonik Industries AG
16.8.1 Company Snapshot
16.8.2 Company Overview
16.8.3 Financial Analysis
16.8.3.1 Net Revenue, 2018-2022
16.8.3.2 R&D, 2018-2022
16.8.3.3 Segment Market Shares, 2022
16.8.3.4 Regional Market Shares, 2022
16.8.4 Service Benchmarking
16.8.5 Strategic Outlook
16.9 FAMAR Health Care Services
16.9.1 Company Snapshot
16.9.2 Company Overview
16.9.3 Service Benchmarking
16.9.4 Strategic Outlook
16.10 Fresenius Kabi AG
16.10.1 Company Snapshot
16.10.2 Company Overview
16.10.3 Financial Analysis
16.10.3.1 Net Revenue, 2018-2022
16.10.3.2 R&D, 2018-2022
16.10.3.3 Segment Market Shares, 2022
16.10.3.4 Regional Market Shares, 2022
16.10.4 Service Benchmarking
16.10.5 Strategic Outlook
16.11 Grifols, S.A.
16.11.1 Company Snapshot
16.11.2 Company Overview
16.11.3 Financial Analysis
16.11.3.1 Net Revenue, 2018-2022
16.11.3.2 R&D, 2018-2022
16.11.3.3 Segment Market Shares, 2022
16.11.3.4 Regional Market Shares, 2022
16.11.4 Service Benchmarking
16.11.5 Strategic Outlook
16.12 Hikma Pharmaceuticals PLC
16.12.1 Company Snapshot
16.12.2 Company Overview
16.12.3 Financial Analysis
16.12.3.1 Net Revenue, 2018-2022
16.12.3.2 R&D, 2018-2022
16.12.3.3 Segment Market Shares, 2022
16.12.3.4 Regional Market Shares, 2022
16.12.4 Service Benchmarking
16.12.5 Strategic Outlook
16.13 Jubilant Pharmova Limited
16.13.1 Company Snapshot
16.13.2 Company Overview
16.13.3 Financial Analysis
16.13.3.1 Net Revenue, 2018-2022
16.13.3.2 Segment Market Shares, 2022
16.13.3.3 Regional Market Shares, 2022
16.13.4 Service Benchmarking
16.13.5 Strategic Outlook
16.14 Lonza
16.14.1 Company Snapshot
16.14.2 Company Overview
16.14.3 Financial Analysis
16.14.3.1 Net Revenue, 2018-2022
16.14.3.2 R&D, 2018-2022
16.14.3.3 Segment Market Shares, 2022
16.14.3.4 Regional Market Shares, 2022
16.14.4 Service Benchmarking
16.14.5 Strategic Outlook
16.15 Patheon Pharma Services (Thermo Fisher Scientific Inc.)
16.15.1 Company Snapshot
16.15.2 Company Overview
16.15.3 Financial Analysis
16.15.3.1 Net Revenue, 2018-2022
16.15.3.2 R&D, 2018-2022
16.15.3.3 Segment Market Shares, 2022
16.15.3.4 Regional Market Shares, 2022
16.15.4 Service Benchmarking
16.15.5 Strategic Outlook
16.16 Pfizer Inc.
16.16.1 Company Snapshot
16.16.2 Company Overview
16.16.3 Financial Analysis
16.16.3.1 Net Revenue, 2018-2022
16.16.3.2 R&D, 2018-2022
16.16.3.3 Segment Market Shares, 2022
16.16.3.4 Regional Market Shares, 2022
16.16.4 Service Benchmarking
16.16.5 Strategic Outlook
16.17 Recipharm AB
16.17.1 Company Snapshot
16.17.2 Company Overview
16.17.3 Financial Analysis
16.17.3.1 Net Revenue, 2018-2022
16.17.4 Service Benchmarking
16.17.5 Strategic Outlook
16.18 Siegfried Holding AG
16.18.1 Company Snapshot
16.18.2 Company Overview
16.18.3 Financial Analysis
16.18.3.1 Net Revenue, 2018-2022
16.18.3.2 R&D, 2018-2022
16.18.3.3 Segment Market Shares, 2022
16.18.4 Service Benchmarking
16.18.5 Strategic Outlook
16.19 Nexus Pharmaceuticals, LLC
16.19.1 Company Snapshot
16.19.2 Company Overview
16.19.3 Service Benchmarking
16.19.4 Strategic Outlook
16.20 Avara Pharmaceutical Services, Inc.
16.20.1 Company Snapshot
16.20.2 Company Overview
16.20.3 Service Benchmarking
16.21 Lilly
16.21.1 Company Snapshot
16.21.2 Company Overview
16.21.3 Financial Analysis
16.21.3.1 Net Revenue, 2018-2022
16.21.3.2 R&D, 2018-2022
16.21.3.3 Regional Market Shares, 2022
16.21.4 Service Benchmarking
16.21.5 Strategic Outlook
16.22 Adare Pharma Solutions
16.22.1 Company Snapshot
16.22.2 Company Overview
16.22.3 Service Benchmarking
16.22.4 Strategic Outlook
16.23 Vetter Pharma
16.23.1 Company Snapshot
16.23.2 Company Overview
16.23.3 Service Benchmarking
16.23.4 Strategic Outlook
16.24 Piramal Pharma Solutions
16.24.1 Company Snapshot
16.24.2 Company Overview
16.24.3 Service Benchmarking
16.24.4 Strategic Outlook

17 Conclusion and Recommendations
17.1 Concluding Remarks from Visiongain
17.2 Recommendations for Market Players

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Snapshot, 2024 & 2034 (US$ Billion, CAGR %)
Table 2 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%): “V” Shaped Recovery
Table 3 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%): “U” Shaped Recovery
Table 4 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%): “W” Shaped Recovery
Table 5 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%): “L” Shaped Recovery
Table 6 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Molecule Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 7 Small Molecule Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 8 Large Molecule Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 9 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 10 Monoclonal Antibodies (mAbs) Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 11 Cytokines Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 12 Insulin Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 13 Peptide Hormones Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 14 Vaccines Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 15 Immunoglobulins Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 16 Blood Factor Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 17 Peptide Antibiotics Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 18 Other Type Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 19 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Application, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 20 Cancer Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 21 Diabetes Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 22 Cardiovascular Diseases Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 23 CNS Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 24 Infectious Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 25 Others Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 26 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Container Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 27 Bottles Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 28 AMPOULES Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 29 Vials Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 30 Prefilled Syringes Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 31 Bags Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 32 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 33 Subcutaneous Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 34 Intravenous Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 35 Intramuscular Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 36 Other Route of Administration Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 37 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Service, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 38 Bioanalytical Testing Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 39 Method Development & Validation Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 40 Stability Testing Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 41 Others Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 42 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 43 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 44 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Molecule Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 45 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 46 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Application, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 47 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Container Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 48 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 49 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Service, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 50 U.S. Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 51 Canada Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 52 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 53 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Molecule Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 54 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 55 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Application, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 56 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Container Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 57 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 58 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Service, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 59 Germany Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 60 UK Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 61 France Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 62 Italy Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 63 Spain Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 64 Switzerland Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 65 Netherlands Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 66 Rest of Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 67 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 68 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Molecule Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 69 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 70 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Application, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 71 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Container Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 72 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 73 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Service, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 74 Japan Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 75 China Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 76 India Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 77 Australia Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 78 South Korea Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 79 South East Asia Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 80 Rest of Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 81 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 82 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Molecule Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 83 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 84 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Application, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 85 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Container Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 86 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 87 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Service, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 88 Brazil Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 89 Mexico Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 90 Argentina Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 91 Rest of Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 92 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 93 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Molecule Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 94 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 95 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Application, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 96 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Container Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 97 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 98 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Service, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 99 GCC Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 100 South Africa Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 101 Egypt Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 102 Rest of MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 103 Aenova Group: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 104 Aenova Group: Service Benchmarking
Table 105 Aenova Group: Strategic Outlook
Table 106 Almac Group: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 107 Almac Group: Service Benchmarking
Table 108 Almac Group: Strategic Outlook
Table 109 WuXi AppTec : Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 110 WuXi AppTec : Service Benchmarking
Table 111 WuXi AppTec : Strategic Outlook
Table 112 Boehringer Ingelheim International GmbH: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 113 Boehringer Ingelheim International GmbH: Service Benchmarking
Table 114 Boehringer Ingelheim International GmbH: Strategic Outlook
Table 115 Catalent, Inc. : Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 116 Catalent, Inc. : Service Benchmarking
Table 117 Catalent, Inc. : Strategic Outlook
Table 118 CordenPharma International: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 119 CordenPharma International: Service Benchmarking
Table 120 CordenPharma International: Strategic Outlook
Table 121 Evonik Industries AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 122 Evonik Industries AG: Service Benchmarking
Table 123 Evonik Industries AG: Strategic Outlook
Table 124 FAMAR Health Care Services: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 125 FAMAR Health Care Services.: Service Benchmarking
Table 126 FAMAR Health Care Services.: Strategic Outlook
Table 127 Fresenius Kabi AG : Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 128 Fresenius Kabi AG: Service Benchmarking
Table 129 Fresenius Kabi AG: Strategic Outlook
Table 130 Grifols, S.A.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 131 Grifols, S.A.: Service Benchmarking
Table 132 Grifols, S.A.: Strategic Outlook
Table 133 Hikma Pharmaceuticals PLC: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 134 Hikma Pharmaceuticals PLC: Service Benchmarking
Table 135 Hikma Pharmaceuticals PLC: Strategic Outlook
Table 136 Jubilant Pharmova Limited : Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 137 Jubilant Pharmova Limited : Service Benchmarking
Table 138 Jubilant Pharmova Limited : Strategic Outlook
Table 139 Lonza : Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 140 Lonza: Service Benchmarking
Table 141 Lonza: Strategic Outlook
Table 142 Patheon Pharma Services (Thermo Fisher Scientific Inc.): Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 143 Patheon Pharma Services (Thermo Fisher Scientific Inc.): Service Benchmarking
Table 144 Patheon Pharma Services (Thermo Fisher Scientific inc.): Strategic Outlook
Table 145 Pfizer Inc. : Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 146 Pfizer Inc.: Service Benchmarking
Table 147 Pfizer Inc.: Strategic Outlook
Table 148 Recipharm AB : Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 149 Recipharm AB: Service Benchmarking
Table 150 Recipharm AB: Strategic Outlook
Table 151 Siegfried Holding AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 152 Siegfried Holding AG: Service Benchmarking
Table 153 Recipharm AB: Strategic Outlook
Table 154 Nexus Pharmaceuticals, LLC: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 155 Nexus Pharmaceuticals, LLC: Service Benchmarking
Table 156 Nexus Pharmaceuticals, LLC: Strategic Outlook
Table 157 Avara Pharmaceutical Services, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 158 Avara Pharmaceutical Services, Inc.: Service Benchmarking
Table 159 Lilly: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 160 Lilly: Service Benchmarking
Table 161 Lilly: Strategic Outlook
Table 162 Adare Pharma Solutions.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 163 Adare Pharma Solutions.: Service Benchmarking
Table 164 Adare Pharma Solutions.: Strategic Outlook
Table 165 Vetter Pharma: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 166 Vetter Pharma: Service Benchmarking
Table 167 Vetter Pharma: Strategic Outlook
Table 168 Piramal Pharma Solutions: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 169 Piramal Pharma Solutions: Service Benchmarking
Table 170 Piramal Pharma Solutions: Strategic Outlook

List of Figures
Figure 1 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Segmentation
Figure 2 Contract Manufacturing Outsourcing (CMO) Market Attractiveness Index by Region
Figure 3 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Molecule Type: Market Attractiveness Index
Figure 4 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Type: Market Attractiveness Index
Figure 5 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Application: Market Attractiveness Index
Figure 6 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Container Type: Market Attractiveness Index
Figure 7 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Route of Administration: Market Attractiveness Index
Figure 8 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Service: Market Attractiveness Index
Figure 9 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market: Market Dynamics
Figure 10 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Region, 2024-2034 (US$ Billion, AGR %): “V” Shaped Recovery
Figure 11 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Region, 2024-2034 (US$ Billion, AGR %): “U” Shaped Recovery
Figure 12 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Region, 2024-2034 (US$ Billion, AGR %): “W” Shaped Recovery
Figure 13 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Region, 2024-2034 (US$ Billion, AGR %): “L” Shaped Recovery
Figure 14 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market: Porter’s Five Forces Analysis
Figure 15 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market: SWOT Analysis
Figure 16 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market: PEST Analysis
Figure 17 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Molecule Type: Market Attractiveness Index
Figure 18 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Molecule Type, 2024-2034 (US$ Billion, AGR %)
Figure 19 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Molecule Type, 2024, 2029, 2034 (%)
Figure 20 Small Molecule Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 21 Small Molecule Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 22 Large Molecule Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 23 Large Molecule Market Share Forecast by Region, 2024 & 2034 (%)
Figure 24 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Type: Market Attractiveness Index
Figure 25 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Type, 2024-2034 (US$ Billion)
Figure 26 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Type, 2024, 2029, 2034 (%)
Figure 27 Monoclonal Antibodies (mAbs) Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 28 Monoclonal Antibodies (mAbs) Market Share Forecast by Region, 2024 & 2034 (%)
Figure 29 Cytokines Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 30 Cytokines Market Share Forecast by Region, 2024 & 2034 (%)
Figure 31 Insulin Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 32 Insulin Market Share Forecast by Region, 2024 & 2034 (%)
Figure 33 Peptide Hormones Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 34 Peptide Hormones Market Share Forecast by Region, 2024 & 2034 (%)
Figure 35 Vaccines Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 36 Vaccines Market Share Forecast by Region, 2024 & 2034 (%)
Figure 37 Immunoglobulins Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 38 Immunoglobulins Market Share Forecast by Region, 2024 & 2034 (%)
Figure 39 Blood Factor Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 40 Blood Factor Market Share Forecast by Region, 2024 & 2034 (%)
Figure 41 Peptide Antibiotics Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 42 Peptide Antibiotics Market Share Forecast by Region, 2024 & 2034 (%)
Figure 43 Other Type Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 44 Other Type Market Share Forecast by Region, 2024 & 2034 (%)
Figure 45 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Application: Market Attractiveness Index
Figure 46 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Application, 2024-2034 (US$ Billion)
Figure 47 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Application, 2024, 2029, 2034 (%)
Figure 48 Cancer Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 49 Cancer Market Share Forecast by Region, 2024 & 2034 (%)
Figure 50 Diabetes Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 51 Diabetes Market Share Forecast by Region, 2024 & 2034 (%)
Figure 52 Cardiovascular Diseases Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 53 Cardiovascular Diseases Market Share Forecast by Region, 2024 & 2034 (%)
Figure 54 CNS Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 55 CNS Market Share Forecast by Region, 2024 & 2034 (%)
Figure 56 Infectious Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 57 Infectious Market Share Forecast by Region, 2024 & 2034 (%)
Figure 58 Others Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 59 Others Market Share Forecast by Region, 2024 & 2034 (%)
Figure 60 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Container Type: Market Attractiveness Index
Figure 61 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Container Type, 2024-2034 (US$ Billion)
Figure 62 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Container Type, 2024, 2029, 2034 (%)
Figure 63 Bottles Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 64 Bottles Market Share Forecast by Region, 2024 & 2034 (%)
Figure 65 AMPOULES Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 66 AMPOULES Market Share Forecast by Region, 2024 & 2034 (%)
Figure 67 Vials Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 68 Vials Market Share Forecast by Region, 2024 & 2034 (%)
Figure 69 Prefilled Syringes Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 70 Prefilled Syringes Market Share Forecast by Region, 2024 & 2034 (%)
Figure 71 Bags Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 72 Bags Market Share Forecast by Region, 2024 & 2034 (%)
Figure 73 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Route of Administration: Market Attractiveness Index
Figure 74 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion)
Figure 75 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Route of Administration, 2024, 2029, 2034 (%)
Figure 76 Subcutaneous Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 77 Subcutaneous Market Share Forecast by Region, 2024 & 2034 (%)
Figure 78 Intravenous Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 79 Intravenous Market Share Forecast by Region, 2024 & 2034 (%)
Figure 80 Intramuscular Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 81 Intramuscular Market Share Forecast by Region, 2024 & 2034 (%)
Figure 82 Other Route of Administration Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 83 Other Route of Administration Market Share Forecast by Region, 2024 & 2034 (%)
Figure 84 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Service: Market Attractiveness Index
Figure 85 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Service, 2024-2034 (US$ Billion)
Figure 86 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Service, 2024, 2029, 2034 (%)
Figure 87 Bioanalytical Testing Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 88 Bioanalytical Testing Market Share Forecast by Region, 2024 & 2034 (%)
Figure 89 Method Development & Validation Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 90 Method Development & Validation Market Share Forecast by Region, 2024 & 2034 (%)
Figure 91 Stability Testing Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 92 Stability Testing Market Share Forecast by Region, 2024 & 2034 (%)
Figure 93 Others Market Forecast by Region, 2024-2034 (US$ Billion)
Figure 94 Others Market Share Forecast by Region, 2024 & 2034 (%)
Figure 95 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Region 2024 and 2034 (Revenue, CAGR%)
Figure 96 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Region 2024, 2029, 2034 (%)
Figure 97 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Region, 2024-2034 (US$ Billion, AGR %)
Figure 98 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Attractiveness Index
Figure 99 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 100 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
Figure 101 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Country, 2024 & 2034 (%)
Figure 102 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Molecule Type, 2024-2034 (US$ Billion, AGR %)
Figure 103 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Molecule Type, 2024 & 2034 (%)
Figure 104 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR %)
Figure 105 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Type, 2024 & 2034 (%)
Figure 106 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Application, 2024-2034 (US$ Billion, AGR %)
Figure 107 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Application, 2024 & 2034 (%)
Figure 108 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Container Type, 2024-2034 (US$ Billion, AGR %)
Figure 109 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Container Type, 2024 & 2034 (%)
Figure 110 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR %)
Figure 111 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Route of Administration, 2024 & 2034 (%)
Figure 112 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Service, 2024-2034 (US$ Billion, AGR %)
Figure 113 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Service, 2024 & 2034 (%)
Figure 114 U.S. Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 115 Canada Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 116 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Attractiveness Index
Figure 117 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 118 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Country, 2024-2034 (US$ Billion)
Figure 119 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Country, 2024 & 2034 (%)
Figure 120 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Molecule Type, 2024-2034 (US$ Billion)
Figure 121 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Molecule Type, 2024 & 2034 (%)
Figure 122 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Type, 2024-2034 (US$ Billion)
Figure 123 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Type, 2024 & 2034 (%)
Figure 124 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Application, 2024-2034 (US$ Billion)
Figure 125 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Application, 2024 & 2034(%)
Figure 126 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Container Type, 2024-2034 (US$ Billion)
Figure 127 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Container Type, 2024 & 2034(%)
Figure 128 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion)
Figure 129 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Route of Administration, 2024 & 2034(%)
Figure 130 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Service, 2024-2034 (US$ Billion)
Figure 131 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Service, 2024 & 2034(%)
Figure 132 Germany Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 133 UK Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 134 France Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 135 Italy Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 136 Spain Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 137 Switzerland Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 138 Netherlands Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 139 Rest of Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 140 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Attractiveness Index
Figure 141 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 142 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Country, 2024-2034 (US$ Billion)
Figure 143 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Country, 2024 & 2034 (%)
Figure 144 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Molecule Type, 2024-2034 (US$ Billion)
Figure 145 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Molecule Type, 2024 & 2034 (%)
Figure 146 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Type, 2024-2034 (US$ Billion)
Figure 147 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Type, 2024 & 2034 (%)
Figure 148 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Application, 2024-2034 (US$ Billion)
Figure 149 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Application, 2024 & 2034 (%)
Figure 150 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Container Type, 2024-2034 (US$ Billion)
Figure 151 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Container Type, 2024 & 2034 (%)
Figure 152 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion)
Figure 153 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Route of Administration, 2024 & 2034 (%)
Figure 154 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Service, 2024-2034 (US$ Billion)
Figure 155 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Service, 2024 & 2034 (%)
Figure 156 Japan Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 157 China Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 158 India Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 159 Australia Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 160 South Korea Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 161 South East Asia Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 162 Rest of Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 163 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Attractiveness Index
Figure 164 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 165 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Country, 2024-2034 (US$ Billion)
Figure 166 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Country, 2024 & 2034 (%)
Figure 167 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Molecule Type, 2024-2034 (US$ Billion)
Figure 168 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Molecule Type, 2024 & 2034 (%)
Figure 169 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Type, 2024-2034 (US$ Billion)
Figure 170 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Type, 2024 & 2034 (%)
Figure 171 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Application, 2024-2034 (US$ Billion)
Figure 172 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Application, 2024 & 2034 (%)
Figure 173 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Container Type, 2024-2034 (US$ Billion)
Figure 174 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Container Type, 2024 & 2034 (%)
Figure 175 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion)
Figure 176 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Route of Administration, 2024 & 2034 (%)
Figure 177 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Service, 2024-2034 (US$ Billion)
Figure 178 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Service, 2024 & 2034 (%)
Figure 179 Brazil Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 180 Mexico Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 181 Argentina Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 182 Rest of Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 183 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Attractiveness Index
Figure 184 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 185 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Country, 2024-2034 (US$ Billion)
Figure 186 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Country, 2024 & 2034 (%)
Figure 187 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Molecule Type, 2024-2034 (US$ Billion)
Figure 188 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Molecule Type, 2024 & 2034 (%)
Figure 189 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Type, 2024-2034 (US$ Billion)
Figure 190 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Type, 2024 & 2034 (%)
Figure 191 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Application, 2024-2034 (US$ Billion)
Figure 192 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Application, 2024 & 2034 (%)
Figure 193 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Container Type, 2024-2034 (US$ Billion)
Figure 194 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Container Type, 2024 & 2034 (%)
Figure 195 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion)
Figure 196 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Route of Administration, 2024 & 2034 (%)
Figure 197 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast by Service, 2024-2034 (US$ Billion)
Figure 198 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Share Forecast by Service, 2024 & 2034 (%)
Figure 199 GCC Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 200 South Africa Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 201 Egypt Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 202 Rest of MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 203 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market: Company Share/Ranking, 2022
Figure 204 Aenova Group: Net Revenue, 2018-2022 (US$ Million, AGR %)
Figure 205 Aenova Group: Segment Market Shares, 2022
Figure 206 Aenova Group: Regional Market Shares, 2022
Figure 207 WuXi AppTec : Net Revenue, 2018-2022 (US$ Million, AGR %)
Figure 208 WuXi AppTec : R&D, 2018-2022 (US$ Million, AGR %)
Figure 209 WuXi AppTec : Segment Market Shares, 2022
Figure 210 WuXi AppTec : Regional Market Shares, 2022
Figure 211 Boehringer Ingelheim International GmbH: Net Revenue, 2018-2022 (US$ Million, AGR %)
Figure 212 Boehringer Ingelheim International GmbH: Segment Market Shares, 2022
Figure 213 Boehringer Ingelheim International GmbH: Regional Market Shares, 2022
Figure 214 Catalent, Inc. : Net Revenue, 2018-2022 (US$ Million, AGR (%)
Figure 215 Catalent, Inc. : Segment Market Shares, 2022
Figure 216 Catalent, Inc. : Regional Market Shares, 2022
Figure 217 Evonik Industries AG: Net Revenue, 2018-2022 (US$ Million, AGR %)
Figure 218 Evonik Industries AG: R&D, 2018-2022 (US$ Million, AGR %)
Figure 219 Evonik Industries AG: Segment Market Shares, 2022
Figure 220 Evonik Industries AG: Regional Market Shares, 2022
Figure 221 Fresenius Kabi AG: Net Revenue, 2018-2022 (US$ Million, AGR %)
Figure 222 Fresenius Kabi AG: R&D, 2018-2022 (US$ Million, AGR %)
Figure 223 Fresenius Kabi AG: Segment Market Shares, 2022
Figure 224 Fresenius Kabi AG: Regional Market Shares, 2022
Figure 225 Grifols, S.A. : Net Revenue, 2018-2022 (US$ Million, AGR %)
Figure 226 Grifols, S.A.: R&D, 2018-2022 (US$ Million, AGR %)
Figure 227 Grifols, S.A.: Segment Market Shares, 2022
Figure 228 Grifols, S.A.: Regional Market Shares, 2022
Figure 229 Hikma Pharmaceuticals Plc: Net Revenue, 2018-2022 (US$ Million, AGR %)
Figure 230 Hikma Pharmaceuticals Plc: R&D, 2018-2022 (US$ Million, AGR %)
Figure 231 Hikma Pharmaceuticals Plc: Segment Market Shares, 2022
Figure 232 Hikma Pharmaceuticals Plc: Regional Market Shares, 2022
Figure 233 Jubilant Pharmova Limited: Net Revenue, 2018-2022 (US$ Million, AGR %)
Figure 234 Jubilant Pharmova Limited : Segment Market Shares, 2022
Figure 235 Jubilant Pharmova Limited .: Regional Market Shares, 2022
Figure 236 Lonza : Net Revenue, 2018-2022 (US$ Million, AGR %)
Figure 237 Lonza : R&D, 2018-2022 (US$ Million, AGR %)
Figure 238 Lonza : Segment Market Shares, 2022
Figure 239 Lonza : Regional Market Shares, 2022
Figure 240 Patheon Pharma Services (Thermo Fisher Scientific Inc.): Net Revenue, 2018-2022 (US$ Million, AGR %)
Figure 241 Patheon Pharma Services (Thermo Fisher Scientific Inc.): R&D, 2018-2022 (US$ Million, AGR %)
Figure 242 Patheon Pharma Services (Thermo Fisher Scientific Inc.): Segment Market Shares, 2022
Figure 243 Patheon Pharma Services (Thermo Fisher Scientific Inc.): Regional Market Shares, 2022
Figure 244 Pfizer Inc. : Net Revenue, 2018-2022 (US$ Million, AGR %)
Figure 245 Pfizer Inc.: R&D, 2018-2022 (US$ Million, AGR %)
Figure 246 Pfizer Inc.: Segment Market Shares, 2022
Figure 247 Pfizer Inc.: Regional Market Shares, 2022
Figure 248 Recipharm AB: Net Revenue, 2018-2022 (US$ Million, AGR %)
Figure 249 Siegfried Holding AG: Net Revenue, 2018-2022 (US$ Million, AGR %)
Figure 250 Siegfried Holding AG: R&D, 2018-2022 (US$ Million, AGR %)
Figure 251 Siegfried Holding AG: Segment Market Shares, 2022
Figure 252 Lilly: Net Revenue, 2018-2022 (US$ Million, AGR %)
Figure 253 Lilly: R&D, 2018-2022 (US$ Million, AGR %)
Figure 254 Lilly: Regional Market Shares, 2022

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野の最新刊レポート

本レポートと同分野の最新刊レポートはありません。

Visiongain 社の最新刊レポート

本レポートと同じKEY WORD（ampoules）の最新刊レポート

よくあるご質問

Visiongain社はどのような調査会社ですか?

英国の調査会社ヴィジョンゲイン社（Visiongain）は、通信とエネルギーのほか、自動車や化学・医薬品、金属など、広範な市場を対象に調査を行っています。自動車市場については、市場全般に関する調査のほ... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

無菌注射薬の製造委託アウトソーシング（CMO）市場レポート：2024-2034

サマリー

目次

図表リスト

Summary

Table of Contents

List of Tables/Graphs

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野の最新刊レポート

Visiongain 社の最新刊レポート

本レポートと同じKEY WORD（ampoules）の最新刊レポート

よくあるご質問

Visiongain社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?